|
Prediction of Metabolic Syndrome by Low Serum Testosterone Levels in Men
Abstract
OBJECTIVE The aim of this analysis was to assess the prospective association of serum testosterone and dehydroepiandrosterone sulfate (DHEAS) levels with incident metabolic syndrome (MetS) in men.
RESEARCH DESIGN AND METHODS Data were obtained from the Study of Health in Pomerania (SHIP), a population-based prospective cohort of adults aged 20–79 years. Analyses were conducted in 1,004 men without baseline MetS defined by National Cholesterol Education Program Adult Treatment Panel III guidelines. Testosterone and DHEAS were categorized by age-specific quartiles and Poisson regression models with relative risks (RRs) and 95% CIs were estimated.
RESULTS After a median follow-up time of 5.0 years, 480 men (47.8%) developed MetS. Testosterone levels decreased with increasing number of MetS components. Testosterone in the lowest quartile predicted MetS (RR 1.38 [95% CI 1.13–1.69]), particularly among men aged 20–39 years (2.06 [1.29–3.29]), even after adjustment for age, smoking, alcohol consumption, physical activity, waist circumference, self-related health, and time of blood sampling. DHEAS levels were not related to incident MetS (0.99 [0.83–1.19]).
CONCLUSIONS Low testosterone but not DHEAS predicts development of MetS in a population-based cohort of 1,004 men aged 20–79 years. Especially in young men aged 20–39 years, results suggest low testosterone as a strong predictor for incident MetS. Assessment of testosterone in young and middle-age men may allow early interventions in the general population
Author Affiliations
-
1Institute of Clinical Chemistry and Laboratory Medicine, Ernst Moritz Arndt University Greifswald, Greifswald, Germany;
-
2Institute for Community Medicine, Ernst Moritz Arndt University Greifswald, Greifswald, Germany;
-
3Department of Cardiology, Ernst Moritz Arndt University Greifswald, Greifswald, Germany;
-
4Institute of Pharmacology, Ernst Moritz Arndt University Greifswald, Greifswald, Germany;
-
5Division of Neuroendocrinology, Department of Neurosurgery, Friedrich-Alexander-University Erlangen, Nuremberg, Germany.
|